SYNAPTICURE INC
Kenilworth, IL · Founded 2019 · CIK 0002038193 · Biotech
Virtual care platform delivering personalized remote clinical management for neurodegenerative disease patients
synapticure.com →- Grants
- $7.9M
- 7 awards
- Sector median: 1
- Raised
- $40M
- 1 Form D · Sep 2024
- 25 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel patient-derived 3D platform for detecting TDP-43 proteinopathy and associated biomarkers for ALS/FTD | $1,171,621 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel patient-derived 3D platform for detecting TDP-43 proteinopathy and associated biomarkers for ALS/FTD | $2,175,360 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel patient-derived 3D platform for detecting TDP-43 proteinopathy and associated biomarkers for ALS/FTD | $1,003,739 | |
| Federal grant | Department of Health and Human Services · Phase I · Mature brain organoid platform for therapeutic screening for ALS/FTD | $499,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Mature brain organoid platform for therapeutic screening for ALS/FTD | $499,999 | |
| Private capital raised | Form D · SEC | $40,145,500 | |
| Federal grant | Department of Health and Human Services · Phase II · 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development | $1,253,527 | |
| Federal grant | Department of Health and Human Services · Phase II · 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development | $1,246,192 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3308 | ORF Biologics, Inc. | — | $2.5M |
| 3309 | Blue Marlin Data Fund, LLC | — | $16M |
| 3310 | ReNewVax Ltd | — | $3.0M |
| 3311 | SYNAPTICURE INC | — | $40M |
| 3312 | Ampersand Health, LLC | — | $7.7M |
| 3313 | CAPTOZYME, INC. | — | $3.4M |
| 3314 | Hope Portal Services, Inc. | — | $250K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Sandra AbrevayaDirector · Executive Officer
- Eric AndersonExecutive Officer
- Jason LangheierDirector
- Joe LeinbachExecutive Officer
- Adam SeabrookDirector
- Brian WallachDirector
- Peter WallachExecutive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.